- FDA Rules for Cigarettes Are a Victory for Public Health, for Science (and for the Earth’s Climate?)
- Legislation Introduced to Codify Stem Cell Rules
- Commissioner Enhances FDA’s Commitment to Personalized Medicine
- Perfecting Policy on Stem Cells
- NIH and FDA Aim to Retool Regulatory Science
- DOE Leads Federal Funding for a Regional Innovation Cluster
- Certainty on the Science of Climate Change
- They’re Not Perfect Cells, But They’re Model Cells
- Genomic Medicine on the March
- President’s Budget Aims to Recharge Regional Innovation
- Event: The Science of Climate Change
- Progress in Bioethics
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
Cell Reprogramming Leaves the Test Tube
Harvard researchers report in the online version of Nature that they have developed a method to directly convert tissue cells (subscription) in a living mouse from one type into another. The breakthrough goes beyond the announcement last fall that scientists at the University of Wisconsin and the University of Kyoto independently developed induced pluripotent stem cells, which are adult cells reverted back to a stem-cell-like state.
Zhou et al. Nature
The development will certainly spark the latest round of discussions over ethical questions involved in stem cell research, but despite the potential for work that builds on this discovery and iPS investigations, human embryonic stem cell research will likely still be an important component of the field for some time to come. Moreover, as James Thomson, leader of the Wisconsin team, made clear last year, hESC research was critical to understanding the hallmarks of pluripotency on the way to iPS cells; and in turn, the Harvard team offers a nod in its opening discussion to that iPS research.
Some researchers who spoke to the Post argued that this latest breakthrough could render human embryonic stem cell research unnecessary, but others pointed out that the science is still too young to make a determination about what is and is not useful. Scientists are still in the process of understanding the complexities of cell functions, and embryonic stem cells are a crucial tool for learning about the cell functions that will enable future cures.
“Embryonic stem cells offer a unique window in human disease and remain a key to the long-term progress of regenerative medicine,” Douglas A. Melton, one of the authors of the new study, told reporter Rob Stein.
The Washington Post also reports that at this early stage, human trials may be five years away. The new process uses a set of engineered adenoviruses to deliver a set of genes to the target exocrine cells in the pancreases of diabetic mice. The combination of three transcription factors then converts these exocrine cells into beta-like cells, which produce insulin. The study indicates that this process appears to take place without the cells passing through a dedifferientiated state, or one similar to that of stem cells.
It is worth noting that the National Institutes of Health supported this remarkable discovery.
(HT to Alta Charo for forwarding the Post story.)
Comments on this article



Yo quiero esta infoemacion en espanol.
September 24th, 2008 at 4:40 pm